In The News





Oxford Professor of Chemistry and Founder of Therapeutic Company Wins Two International Awards
Business & Innovation Magazine
Dame Carol Robinson DBE, FRS, FRSC, FMedSci, Oxford University’s first female Professor of Chemistry, former president of the Royal Society of...

Finding needles in haystacks: OMass unveils pipeline aimed at tough-to-drug targets

Is big pharma falling back in love with small molecules?
New approaches to small-molecule design allow difficult targets to be addressed, such as the G protein-coupled receptors (GPCR) on cell...
UK Biotech Closes €50M Series A for GPCR Drug Discovery
Oxford-based OMass Therapeutics has extended its Series A round by €33M to fund the spectrometry-assisted development of drugs targeting G...

UK biotech OMass raises £27.5m for GPCR drug discovery
Oxford, UK-based OMass Therapeutics has extended its first-round financing to more than £41 million ($53 million), to help it fund...
SCRIP: Finance Watch: VCs Are Sharing The Wealth With More Biopharmas
The UK-based start-up OMass Therapeutics said on 17 February that it completed a series A extension totaling £27.5m ($35.7m) from...
Drug discovery in HD: Oxford spinoff’s mass spectrometry approach scores fresh funding
The technology used to detect explosives at airports — mass spectrometry — is being piloted as an engine for drug...
Financings for Feb. 18, 2020
Omass Therapeutics, of Oxford, U.K., which is harnessing mass spectrometry and other biophysical technologies to drive drug discovery, said it...
Women in Bio: OMass Taps Biogen Vet Nathalie Franchimont for Board of Directors
When U.K.-based OMass Therapeutics began the search for a new member for its board of directors, Chief Executive Officer Rosamond...
BRIEF – OMass Therapeutics raises £14 million in series A round
The Pharma Letter
Oxford, UK-based OMass Therapeutics has raised £14 million ($18 million) in a series A financing round, led by Syncona, alongside...

Roivant joins forces with Korea’s iNtRON Bio to fight superbugs; Evotec inks deal to leverage AI to develop drugs
OMass Therapeutics, which was spun out of Oxford in 2016, has secured £14 million in a Series A round of...
OMass applying gas mass spec tech to human health with $18M series A round
OMass Therapeutics Ltd. has closed a £14 million (US$18 million) series A round, equipping it to commence commercialization of a...
OMass Therapeutics Pivots From Services To Drug Discovery With Novel Mass Spect Technology
A new UK biotech, OMass Therapeutics, has been spun out of the chemistry department at the University of Oxford to...